Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial is evaluating adding an individualized cancer vaccine to durvalumab, tremelimumab, and chemotherapy in patients with metasta…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) [Phase 3]
A Phase 3 study of sacituzumab govitecan (Sac-TMT, MK-2870) for breast cancer is currently recruiting. The trial includes patients with trip…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of LY4175408 in Participants With Advanced Cancer [Phase 1]
A Phase 1 clinical trial evaluating LY4175408 in participants with advanced cancers, including non-small cell lung cancer, small cell lung c…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
This is an open-label, multicenter expanded access protocol to provide leronlimab to patients with locally advanced or metastatic triple-neg…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer [Phase 1]
Phase 1 clinical trial update for CF33-hNIS-antiPDL1 in metastatic triple-negative breast cancer shows the study is currently ACTIVE_NOT_REC…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer [Phase 2]
This Phase 2 trial assesses avelumab in combination with binimetinib, sacituzumab govitecan, or liposomal doxorubicin in patients with stage…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases [Phase 2]
A Phase II study is evaluating the combination of pembrolizumab and lenvatinib in patients with triple-negative breast cancer, non-small cel…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care [Phase 3]
A Phase III study comparing JSKN016 to physician's choice in patients with triple-negative breast cancer who have failed standard of care is…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: FUSCC Refractory TNBC Platform Study (FUTURE2.0) [Phase 2]
A Phase 2 clinical trial update for the FUTURE2.0 platform study at Fudan University in refractory triple-negative breast cancer, currently …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Update on a breast cancer neoadjuvant systemic therapy trial, currently recruiting and covering ER-positive, HER2-positive, and triple-negat…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for Enzelkitug as a single agent and in combination with a checkpoint inhibitor in adults with locally advance…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: JS207 Combination Therapy in Triple-negative Breast Cancer [Phase 2]
Phase 2 trial of JS207 combination therapy for triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC [NA]
Description of a pilot clinical trial evaluating aerobic exercise during immune checkpoint inhibitor therapy for patients with early-stage t…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluates carboplatin and paclitaxel with or without panitumumab in invasive triple-negative breast cancer. The stu…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
An upcoming clinical trial is evaluating ovarian toxicity outcomes in patients with triple-negative breast cancer treated with immunotherapy…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of XMT-1660 in Participants With Solid Tumors [Phase 1]
Phase 1 study of XMT-1660 in participants with solid tumors is currently recruiting. The trial lists indications including triple-negative b…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial comparing gemcitabine to paclitaxel in metastatic triple-negative breast cancer among Caribbean women of African ancestry; cur…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Phase 1 Study of CLR 125 in Triple Negative Breast Cancer [Phase 1]
Phase 1 study of CLR 125 for triple-negative breast cancer is currently recruiting, representing an early clinical investigation by Cellecta…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients [Phase 2]
A Phase 2 clinical trial is evaluating whether vitamin D supplementation affects pathologic complete response rates in vitamin D-deficient p…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study of LY4101174 in participants with recurrent, advanced or metastatic solid tumors is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer [Phase 1]
This Clinical Trial Update describes a Phase 1 study evaluating the addition of BAY 1895344 to standard chemotherapy (cisplatin or cisplatin…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours [Phase 1]
Phase 1 trial of GCAR1 CAR T-cell therapy for GPNMB-expressing solid tumors; study targets alveolar soft-part sarcoma, renal cell carcinoma,…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. [Phase 1, Phase 2]
A Phase I/II clinical trial is evaluating BLEX 404 in combination with docetaxel for advanced or metastatic triple-negative breast cancer; t…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer [Phase 1]
This clinical trial update reports testing the addition of berzosertib to radiation therapy in patients with chemotherapy-resistant triple-n…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating serial circulating tumor DNA monitoring during adjuvant capecitabine in early triple-negative breast cancer is cu…